1. Home
  2. RNTX vs VYNE Comparison

RNTX vs VYNE Comparison

Compare RNTX & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNTX
  • VYNE
  • Stock Information
  • Founded
  • RNTX N/A
  • VYNE 2003
  • Country
  • RNTX United States
  • VYNE United States
  • Employees
  • RNTX N/A
  • VYNE N/A
  • Industry
  • RNTX Biotechnology: Pharmaceutical Preparations
  • VYNE Biotechnology: Pharmaceutical Preparations
  • Sector
  • RNTX Health Care
  • VYNE Health Care
  • Exchange
  • RNTX Nasdaq
  • VYNE Nasdaq
  • Market Cap
  • RNTX 43.3M
  • VYNE 41.9M
  • IPO Year
  • RNTX 2017
  • VYNE 2018
  • Fundamental
  • Price
  • RNTX N/A
  • VYNE $2.70
  • Analyst Decision
  • RNTX
  • VYNE Strong Buy
  • Analyst Count
  • RNTX 0
  • VYNE 2
  • Target Price
  • RNTX N/A
  • VYNE $6.88
  • AVG Volume (30 Days)
  • RNTX N/A
  • VYNE 153.7K
  • Earning Date
  • RNTX N/A
  • VYNE 02-27-2025
  • Dividend Yield
  • RNTX N/A
  • VYNE N/A
  • EPS Growth
  • RNTX N/A
  • VYNE N/A
  • EPS
  • RNTX N/A
  • VYNE N/A
  • Revenue
  • RNTX N/A
  • VYNE $493,000.00
  • Revenue This Year
  • RNTX N/A
  • VYNE $28.30
  • Revenue Next Year
  • RNTX N/A
  • VYNE N/A
  • P/E Ratio
  • RNTX N/A
  • VYNE N/A
  • Revenue Growth
  • RNTX N/A
  • VYNE 39.27
  • 52 Week Low
  • RNTX N/A
  • VYNE $1.57
  • 52 Week High
  • RNTX N/A
  • VYNE $4.30
  • Technical
  • Relative Strength Index (RSI)
  • RNTX N/A
  • VYNE 43.45
  • Support Level
  • RNTX N/A
  • VYNE $2.57
  • Resistance Level
  • RNTX N/A
  • VYNE $4.30
  • Average True Range (ATR)
  • RNTX 0.00
  • VYNE 0.39
  • MACD
  • RNTX 0.00
  • VYNE -0.11
  • Stochastic Oscillator
  • RNTX 0.00
  • VYNE 7.51

About VYNE VYNE Therapeutics Inc.

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

Share on Social Networks: